Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

83.80CHF
15 Dec 2017
Change (% chg)

CHF-0.05 (-0.06%)
Prev Close
CHF83.85
Open
CHF84.05
Day's High
CHF84.05
Day's Low
CHF83.35
Volume
18,908,583
Avg. Vol
4,290,558
52-wk High
CHF85.40
52-wk Low
CHF69.50

Latest Key Developments (Source: Significant Developments)

Novartis says Crizanlizumab Shown To Prolong Time To Patients' First Sickle Cell Pain Crisis
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Novartis Ag says::Its drug crizanlizumab was shown to prolong time to patients' first sickle cell pain crisis in a study..The drug approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data..Discussions with health authorities continue; FDA filing anticipated by end of 2018 pending outcome of ongoing healthy volunteer bridging study..  Full Article

Novartis Division Sandoz Says New Phase I Data Showing Proposed Biosimilar Pegfilgrastim Matches Reference Medicine‍​
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Novartis ::DIVISION SANDOZ SAYS NEW PHASE I DATA SHOWING PROPOSED BIOSIMILAR PEGFILGRASTIM MATCHES REFERENCE MEDICINE‍​.  Full Article

Novartis Says Premenopausal Women Taking Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Novartis Ag ::NOVARTIS KISQALI IS FIRST AND ONLY CDK4/6 INHIBITOR TO SHOW SUPERIOR MEDIAN PFS COMPARED TO ORAL ENDOCRINE THERAPY AS FIRST-LINE TREATMENT IN A PROSPECTIVE, RANDOMIZED PHASE III TRIAL DEDICATED TO PREMENOPAUSAL WOMEN WITH HR+/HER2- ADVANCED BREAST CANCER.NOVARTIS - PREMENOPAUSAL WOMEN TAKING KISQALI BENEFITED FOR LONGER TIME UNTIL HEALTH-RELATED QOL DETERIORATION VERSUS THOSE TAKING ENDOCRINE THERAPY ALONE.NOVARTIS - WOMEN TAKING KISQALI ALSO HAD A "CLINICALLY MEANINGFUL" IMPROVEMENT IN PAIN SYMPTOMS AS EARLY AS EIGHT WEEKS.NOVARTIS - NO NEW SAFETY SIGNALS WERE OBSERVED IN MONALEESA-7 TRIAL.NOVARTIS AG - COMBINATION TREATMENT WITH KISQALI WAS WELL TOLERATED WITH A DISCONTINUATION RATE DUE TO ADVERSE EVENTS OF 3.6%.  Full Article

ACCC Institutes Proceedings Against GSK, Novartis
Tuesday, 5 Dec 2017 

Dec 6 (Reuters) - Australian Competition and Consumer Commission:INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD (GSK) AND NOVARTIS CONSUMER HEALTH AUSTRALASIA.PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.SEEKING DECLARATIONS, INJUNCTIONS, PECUNIARY PENALTIES, A PUBLICATION ORDER, THE IMPOSITION OF A COMPLIANCE PROGRAM AND COSTS.  Full Article

Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Advanced Accelerator Applications Sa ::ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS.ADVANCED ACCELERATOR APPLICATIONS - CO'S BOARD RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS.  Full Article

‍Novartis' Rydapt Approved Following Priority Review By Health Canada​
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Novartis Ag ::‍NOVARTIS PHARMACEUTICALS CANADA - RYDAPT (MIDOSTAURIN) HAS BEEN APPROVED FOLLOWING A PRIORITY REVIEW BY HEALTH CANADA​.  Full Article

Novartis says Cosentyx shows long-term efficacy in nail and palmoplantar psoriasis
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Novartis AG ::NOVARTIS AG - NOVARTIS' COSENTYX® IS FIRST BIOLOGIC TO SHOW LONG-TERM EFFICACY IN NAIL AND PALMOPLANTAR PSORIASIS, WHICH CAN IMPACT UP TO 90% OF PSORIASIS PATIENTS.  Full Article

‍Novartis announces phase three strive data published in NEJM
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Novartis Ag ::‍NOVARTIS ANNOUNCES PHASE III STRIVE DATA PUBLISHED IN NEJM DEMONSTRATING SIGNIFICANT AND SUSTAINED EFFICACY OF ERENUMAB IN MIGRAINE PREVENTION​.NOVARTIS - NEJM PUBLISHED POSITIVE RESULTS FROM 6-MONTH PHASE III STRIVE STUDY EVALUATING ERENUMAB IN PREVENTION OF EPISODIC MIGRAINE​.- ‍ERENUMAB DELIVERED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCES FROM PLACEBO FOR ALL PRIMARY AND SECONDARY ENDPOINTS​.‍FIFTY PERCENT OF PATIENTS TAKING ERENUMAB 140MG HAD THEIR MIGRAINE DAYS CUT BY AT LEAST HALF​.  Full Article

Novartis says ‍Ultibro Breezhaler improved COPD patients' lung function
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Novartis Ag ::SAYS ‍ULTIBRO® BREEZHALER® SIGNIFICANTLY IMPROVED COPD PATIENTS' LUNG FUNCTION AFTER DIRECT SWITCH FROM SERETIDE​.  Full Article

Novartis's Tasigna wins additional EU approval
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Novartis AG :Novartis drug Tasigna (nilotinib) secures eu approval for first and second-line treatment of ph+ cml-cp in children.  Full Article

Photo

P&G appoints Peltz to board despite losing proxy battle

Procter & Gamble Co said it appointed Nelson Peltz to its board despite the activist investor narrowly losing a months-long proxy fight, the biggest ever involving a U.S. company.